B Nhl clinical trials

Explore recruiting b nhl clinical trials.

Recruiting b nhl studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

B Nhl trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody®-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma

Spain, Sweden, Italy, Belgium, Finland, France +4 more

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Modular Phase I/II Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Efficacy of AZD4512 Monotherapy or in Combination With Other Anticancer Agent(s), in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (B-NHL) (Lumi-NHL)

Italy

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A Single-Arm, Open-Label, Multicenter, Phase 1b/2 Study Evaluating the Safety and Efficacy of AUTO1 (obecabtagene autoleucel [obe-cel]) in Pediatric Patients with CD19-positive Relapsed/Refractory (R/R) B cell Acute Lymphoblastic Leukemia (B ALL) or R/R Aggressive Mature B Cell Non–Hodgkin Lymphoma (B NHL)

Spain

Human Pharmacology (Phase I)- Other EU CTIS Study details

B-NHL 2013 - Treatment protocol of the NHL-BFM and the NOPHO study groups for mature aggressive B-cell lymphoma and leukemia in children and adolescents

Norway, Germany, Finland, Sweden, Austria, Denmark +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A PHASE I/II STUDY TO INVESTIGATE THE SAFETY AND FEASIBILITY OF POINT-OF-CARE HUMAN-CD19 TARGETING CAR T-CELLS IN PAEDIATRIC AND YOUNG ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-CELL MALIGNANCIES (PACMAN)

Netherlands

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Phase I/II study of anti-CD19 Chimeric Antigen Receptor-Expressing T cells in pediatric patients affected by relapsed/refractory CD19+ Acute Lymphoblastic Leukemia and Diffuse Large B Cell Lymphoma (DLBCL) or Primary Mediastinal B Cell Lymphoma (PML)

Italy

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

B Nhl trials by city

B Nhl in Toronto B Nhl in Vancouver B Nhl in Montreal B Nhl in Calgary B Nhl in Edmonton B Nhl in Ottawa B Nhl in Winnipeg B Nhl in Quebec City B Nhl in Hamilton B Nhl in Kitchener B Nhl in London B Nhl in Halifax B Nhl in New York B Nhl in Los Angeles B Nhl in Chicago B Nhl in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease